Skip to main content

RiaSTAP FDA Approval History

FDA Approved: Yes (First approved January 16, 2009)
Brand name: RiaSTAP
Generic name: Fibrinogen Concentrate (Human)
Company: CSL Behring
Treatment for: Congenital Fibrinogen Deficiency

RiaSTAP (Fibrinogen Concentrate (Human)) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. RiaSTAP is not indicated for dysfibrinogenemia.

Development timeline for RiaSTAP

Jan 20, 2009Approval CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.